All In Biotech

Drug Trial Radar · NCT00366249

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes

Last checked: Nov 19, 2026Latest source record: Apr 28, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,061 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,061

Actual

Start

Jan 2007

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.

Conditions

  • Bacterial Infections
  • Diabetic Foot
  • Osteomyelitis

Interventions

  • TigecyclineDrug

    150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis

  • ErtapenemDrug

    Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Clinical Response of Cure Vs. Failure.Time frame: Test of cure visit (TOC): Assessed at least 12 days post last dose
  2. Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.Time frame: Test of cure visit (TOC): Assessed at least 12 days post last dose

Locations

211 sites in 39 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Northridge, California

  • Site not named

    San Francisco, California

  • Site not named

    Sylmar, California

  • Site not named

    Torrance, California

  • Site not named

    Orlando, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Chicago, Illinois

  • Site not named

    Evanston, Illinois

  • Site not named

    North Chicago, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Somers Point, New Jersey

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Lima, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    West Reading, Pennsylvania

  • Site not named

    Columbia, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Buenos Aires, Buenos Aires, Argentina

  • Site not named

    Chivilcoy, Buenos Aires, Argentina

  • Site not named

    Ciudadela, 3 de Febrero, Buenos Aires, Argentina

  • Site not named

    Ciudadela, 3 de Febrero, Buenos Aires, Argentina

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.